Takeda and Pfizer to Co-Promote Takeda's Actos~R (pioglitazone HCI) for the Treatment of Type 2 Diabetes in China

摘要

Takeda Pharmaceutical Company Limited ["Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos~R (pioglitazone HC1) with Tianjin Takeda Pharmaceuticals in China. The exclusive co-promotion agreement will build on the current sales capability for Actos in China by increasing the number of medical representatives supporting the sales and marketing of the product and expanding the product reach utilizing theterritory coverage of Pfizer in China, the largest multinational pharmaceutical company in China. Pfizer's Chinese affiliate will receive a fixed ratio of Actos net sales.